Breast cancer is the most common malignancy amongst women in the developed world. For patients with hormone-sensitive breast cancer eligible for adjuvant hormonal therapy, it is important to know if the ovaries are (still) functional or not. Indeed, the choice for a specific adjuvant hormonal treatment depends on the menopausal status of an individual woman. The currently available measures to determine the menopausal status are conflicting. Until better measures become available, we propose a practical guideline enabling an optimal choice of adjuvant hormonal therapy for women with a hormone receptor positive breast cancer taking into account uncertainties about their menopausal status.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.critrevonc.2012.06.005 | DOI Listing |
ESMO Open
January 2025
Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
Background: Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy of anticancer agents. In the phase III PALLAS trial, the addition of palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use of PPIs affected survival outcomes in patients treated with palbociclib in PALLAS.
View Article and Find Full Text PDFEur J Clin Microbiol Infect Dis
January 2025
Department of Epidemiology, School of Public Health, Shanxi Medical University, 56, Xinjian Nan Road, Taiyuan, 030001, China.
Background: High-risk human papillomavirus (HR-HPV) infection is the primary cause of cervical cancer and precancerous lesions. Approximately 35% of women with low-grade cervical intraepithelial neoplasia (CIN1) may experience persistence or progression to high-grade lesions. Yet, the dynamic characteristics of HR-HPV infection in women with CIN1 remain unclear.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Background: Endogenous estrogen history across the life course may be associated with better cognitive maintenance. Few large longitudinal studies have evaluated this prospectively, and results have been inconsistent. We assessed the association of reproductive span, an indicator of endogenous estrogen history, with cognitive change in older women.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Michigan, Ann Arbor, MI, USA.
Background: Menopause is a time of accelerated loss of physical function, illustrated by challenges to mobility, speed, strength, and performance of activities of daily living. Physical function is associated with cognitive function, but there are limited data exploring this association among older women. In a cohort of older adult women, we hypothesize better performance on measures of physical function will be associated with better cognitive performance.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, San Diego, La Jolla, CA, USA.
Background: Women are more likely to experience sleep problems than men, especially during and after menopausal transition. Sleep disturbances are related to memory decline and the development of Alzheimer's disease (AD), which is also more common among women. While research on habitual sleep patterns in aging has largely focused on mean sleep outcomes across nights, few studies have examined the potentially harmful effects of night-to-night variability in sleep quality on AD biomarkers and memory function.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!